As Il5 mRNA levels were unaffected by Ruxolitinib, yet eosinophilia was greatly reduced in SA+R mice, our observations suggest that both IL-4 and IL-13 drive eosinophilic inflammation in the lung. This evidence concerns the gene IL13 and Increased total eosinophil count.